PMC7446518_01
Periaortic nodule response to entrectinib. Axial and coronal images at (A, D) baseline, (B, E) 4 weeks, and (C, F) 6 months. The periaortic nodule (red arrow) was [18F]fluorodeoxyglucose avid at baseline (standardized uptake value, 5.23) but was not visualized at 4 weeks and remains absent.
PO.17.00105f1.jpg
PMC7446518_01_PO.17.00105f1.jpg
F1
At baseline, positron emission tomography/computed tomography imaging revealed a left periaortic soft tissue nodule (Figs 1A and 1D) and a solitary liver metastasis not well visualized with computed tomography alone (Figs 2A and 2D). After 4 weeks of therapy, the periaortic nodule was no longer visualized (Figs 1B and 1E) and remained absent 6 months after starting therapy (Figs 1C and 1F).
Liver metastasis response to entrectinib. Axial and coronal images at (A, D) baseline, (B, E) 4 weeks, and (C, F) 6 months. The liver metastasis (red arrow) was not well visualized on computed tomography images alone but was [18F]fluorodeoxyglucose avid at baseline (standardized uptake value, 12.02) but was not visualized at 4 weeks and remains absent.
PO.17.00105f2.jpg
PMC7446518_01_PO.17.00105f2.jpg
F2
At baseline, positron emission tomography/computed tomography imaging revealed a left periaortic soft tissue nodule (Figs 1A and 1D) and a solitary liver metastasis not well visualized with computed tomography alone (Figs 2A and 2D). The hypermetabolic liver metastasis had also resolved (Figs 2B and 2E) and was also absent at 6 months (Figs 2C and 2F).